Endotrophin as a Marker of Complications in a Type 2 Diabetes Cohort
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
OBJECTIVE We investigated endotrophin, a profibrotic signaling molecule reflecting collagen VI formation, in serum and urine as risk marker for complications to type 2 diabetes. RESEARCH DESIGN AND METHODS Endotrophin was measured in 774 individuals with type 2 diabetes. Outcomes included a composite kidney end point, first major adverse cardiovascular event (MACE), mortality, progression of albuminuria, incident heart failure, and sight-threatening eye disease. Adjusted Cox proportional hazards models were applied. RESULTS Doubling of serum endotrophin was associated with the kidney end point (n 5 49; hazard ratio 1.80 [95% CI 1.13–2.87]), first MACE (n 5 66; 1.54 [1.04–2.28]), mortality (n 5 156; 1.69 (1.31–2.19]), and incident heart failure (n 5 42; 1.63 [1.02–2.60]). A doubling of urine endotrophin was associated with progression of albuminuria (n 5 85; 1.20 [1.04–1.39]). CONCLUSIONS Serum endotrophin was a risk marker for mortality and kidney and cardiovascular complications in type 2 diabetes. Urine endotrophin was a marker for albu-minuria progression.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Diabetes Care |
| Vol/bind | 45 |
| Udgave nummer | 11 |
| Sider (fra-til) | 2746-2748 |
| Antal sider | 3 |
| ISSN | 0149-5992 |
| DOI | |
| Status | Udgivet - nov. 2022 |
Bibliografisk note
Funding Information:
Acknowledgments. The authors thank the participants and the laboratory technicians who collected the biobank material in the StenoDot trial at Steno Diabetes Center Copenhagen. Funding. This study was supported by the Danish Research Foundation and the Innovation Fund Denmark (0172-00270B). Duality of Interest. P.F.R. and T.W.H. have shares in Novo Nordisk A/S. P.R. has received research support and personal fees from AstraZeneca and Novo Nordisk and personal fees from Astellas, Boehringer Ingelheim, Eli Lilly, Gilead, Mundi-pharma, Sanofi, and Vifor. A.L.M., F.G., M.A.K., and D.G.K.R. are full-time employees at Nordic Bioscience. Nordic Bioscience is a privately owned, small-to medium-sized enterprise partly focused on the development of biomarkers. F.G., M.A.K., and D.G.K.R. hold stocks in Nordic Bioscience. The patent for the ELISA used to measure endotrophin levels is owned by Nordic Bioscience. The funders provided support in the form of salaries for authors A.L.M., F.G., M.A.K., and D.G.K.R. A.L.M., F.G., M.A.K., and D.G.K.R., who are employees of Nordic Bioscience, performed the laboratory analysis and revised the manuscript. No other potential conflicts of interest relevant to this article were reported.
Publisher Copyright:
© 2022 by the American Diabetes Association.
ID: 327067029